Skip to main content

Table 1 Patient and tumor characteristics at baseline (N = 62)

From: FOLFIRI® and Bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms

 

N

(%)

Age (years)

  

 Median

67.9

 

 Range

60.4–75.4

 

Sex

  

 Male

25

(40.3)

 Female

37

(59.7)

ECOG performance status

  

 0

20

(32.3)

 1

39

(62.9)

 2

3

(4.8)

Primary tumor location

  

 Colon

53

(84.5)

 Rectum

9

(14.5)

Metastases

  

 Liver

54

(87.1)

 Lung

28

(45.2)

 Lymph nodes

16

(25.8)

 Peritoneum

17

(27.4)

 Others

14

(22.5)

Number of organs involved (measurable)

  

 1

8

(12.9)

 2

12

(19.3)

 ≥ 3

42

(66.1)

Adjuvant chemotherapy

17

(27.4)

Radiotherapy

8

(12.9)

Surgery

50

(80.6)